Europe Vitrification Market Size, Share & Industry Trends Analysis Report By Specimen (Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm), By End-use, By Country and Growth Forecast, 2023 - 2030

The Europe Vitrification Market would witness market growth of 16.4% CAGR during the forecast period (2023-2030).

The rise in infertility cases fuels rising demand for the preservation of fertility solutions and expands the market. Additional factors that have driven up demand for vitrification services include the legalization of same-sex marriage and an upsurge in single-parent households across several countries.

Numerous causes, such as the development of fertility preservation treatments, the delay of childbearing because of sociodemographic factors, and rising public awareness of reproductive health, are fueling the market's expansion. Its therapeutic application has increased due to numerous investigations and trials proving vitrification is more effective than gradual freezing. The market is driven by most Invitro Fertilization (IVF) clinics that use this technique to freeze eggs and embryos and increase patient success rates. The numerous businesses offering affordable specimen preservation services also grow the market's potential.

Spain continues to be the most active nation in Europe for assisted reproduction, with 140,909 treatment cycles completed, according to a 2019 study from the European Society of Human Reproduction and Embryology (ESHRE). Spain is still setting the pace ahead of Germany (969,226), France (104,733), and Russia (121,235 cycles). ESHRE keeps track of various processes, including egg donation, intrauterine insemination, and IVF. Additionally, existing IVF services and the availability of good healthcare infrastructure are significantly boosting the growth of the entire regional market in Europe.

The Germany market dominated the Europe Vitrification Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,953.8 million by 2030. The UK market is exhibiting a CAGR of 15.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 17.3% during (2023 - 2030).

Based on Specimen, the market is segmented into Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm. Based on End-use, the market is segmented into IVF Clinics, and Biobanks. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitüb GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech

Scope of the Study

Market Segments Covered in the Report:

By Specimen

• Oocytes
• Devices
• Kits & Consumables
• Embryo
• Devices
• Kits & Consumables
• Sperm

By End-use

• IVF Clinics
• Biobanks

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Vitrolife AB
• Genea Limited (Liverpool Partners Group)
• NidaCon International AB
• Minitüb GmbH
• Cryo Bio System (IMV Technologies Group)
• CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.)
• FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation)
• Biotech, Inc.
• Kitazato Corporation
• Shenzhen VitaVitro Biotech

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free